ストックスクリーナーアプリを入手
6.62
2.22%
-0.15
Aligos Therapeutics Inc (ALGS) 最新ニュース
ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
ALGS stock rallies 16% after-hours on $25M cash boost from China hepatitis B drug deal - MSN
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment - MSN
Aligos Therapeutics stock is trending overnight: Here's what's going on with ALGS stock - MSN
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Aligos Therapeutics Secures $25M Upfront Payment in Licensing De - GuruFocus
Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock - Benzinga
Aligos receives $25M upfront payment from China licensing deal - Investing.com UK
Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech - Moomoo
Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com - Investing.com South Africa
Why is Aligos Therapeutics stock surging today? By Investing.com - Investing.com Canada
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos receives $25M upfront payment from China licensing deal By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock jumps on $25M China licensing deal - Investing.com
China grants breakthrough status to Aligos’ HBV drug after $25M deal - Stock Titan
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Discipline and Rules-Based Execution in ALGS Response - Stock Traders Daily
Form 4 Aligos Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Form 4 Aligos Therapeutics Inc For: 29 June - Investing.com India
Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 - Stock Titan
Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike - Stock Titan
Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike - Stock Titan
Director at Aligos (ALGS) granted option on 5,860 common shares - Stock Titan
Aligos Therapeutics (ALGS) director gets 5,860-share stock option grant - Stock Titan
Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50 - Stock Titan
Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Index - marketscreener.com
Aligos Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALGS) - TradingView
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell Microcap Index - marketscreener.com
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Value Benchmark - marketscreener.com
Aligos Therapeutics Shareholders Approve Directors and Governance Changes - TipRanks
Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay - Stock Titan
ALGS Forecast — Price Target — Prediction for 2027 - TradingView
5WK0 Forecast — Price Target — Prediction for 2027 - TradingView
Aligos Therapeutics, Inc. Actuals & Estimates (DUS:5WK0) - TradingView
Price to sales forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to EBIT forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to revenue forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to EBITDA forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Price to book forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Price to earnings forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake - TradingView
Aligos Therapeutics (NASDAQ: ALGS) CEO discloses 5.6% stake in Schedule 13D filing - Stock Titan
Aligos Therapeutics Inc (ALGS) Institutional Confidence - TradingKey
Aligos Therapeutics Inc (ALGS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Behavioral Patterns of ALGS and Institutional Flows - Stock Traders Daily
Aligos Therapeutics Inc (ALGS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aligos Therapeutics Inc (ALGS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aligos Therapeutics Inc (ALGS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aligos Therapeutics Inc (ALGS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
2.64%
大文字化:
|
ボリューム (24 時間):